References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailStress echocardiography expert consensus statement-executive summary: european association of echocardiography (a registrated branch of the ESC).
Sicari, R.; Nihoyannopoulos, P.; Evangelista, A. et al

in European Heart Journal (2009), 30(3), 278-89

Detailed reference viewed: 153 (2 ULiège)
Full Text
Peer Reviewed
See detailAppropriate myocardial revascularization: a joint viewpoint from an interventional cardiologist and a cardiac surgeon.
Wijns, William; Kolh, Philippe ULiege

in European Heart Journal (2009), 30(18), 2182-5

Detailed reference viewed: 36 (3 ULiège)
Full Text
Peer Reviewed
See detailRenal insufficiency after cardiac surgery: a challenging clinical problem.
Kolh, Philippe ULiege

in European Heart Journal (2009), 30(15), 1824-7

Detailed reference viewed: 38 (2 ULiège)
Full Text
Peer Reviewed
See detailESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
Daemen, Joost; Simoons, Maarten L.; Wijns, William et al

in European Heart Journal (2009), 30(2), 152-61

Detailed reference viewed: 30 (1 ULiège)
Full Text
Peer Reviewed
See detailA frozen heart.
DAVIN, Laurent ULiege; Legrand, Victor ULiege; Legrand, Delphine

in European Heart Journal (2009), 30(15), 1827

Detailed reference viewed: 33 (2 ULiège)
Full Text
Peer Reviewed
See detailMechanism of improvement in mitral regurgitation after cardiac resynchronization therapy.
Ypenburg, Claudia; Lancellotti, Patrizio ULiege; Tops, Laurens F et al

in European Heart Journal (2008), 29(6), 757-65

AIMS: The aim of the current study was to evaluate the relationship between the presence of left ventricular (LV) dyssynchrony at baseline and acute vs. late improvement in mitral regurgitation (MR) after ... [more ▼]

AIMS: The aim of the current study was to evaluate the relationship between the presence of left ventricular (LV) dyssynchrony at baseline and acute vs. late improvement in mitral regurgitation (MR) after cardiac resynchronization therapy (CRT). METHODS AND RESULTS: Sixty eight patients consecutive (LV ejection fraction 23 +/- 8%) with at least moderate MR (>or=grade 2+) were included. Echocardiography was performed at baseline, 1 day after CRT initiation and at 6 months follow-up. Speckle tracking radial strain was used to assess LV dyssynchrony at baseline. The majority of patients improved in MR after CRT, with 43% improving immediately after CRT, and 20% improving late (after 6 months) after CRT. Early and late responders had similar extent of LV dyssynchrony (209 +/- 115 ms vs. 190 +/- 118 ms, P = NS); however, the site of latest activation in early responders was mostly inferior or posterior (adjacent to the posterior papillary muscle), whereas the lateral wall was the latest activated segment in late responders. CONCLUSION: Current data suggest that the presence of baseline LV dyssynchrony is related to improvement in MR after CRT. LV dyssynchrony involving the posterior papillary muscle may lead to an immediate reduction in MR, whereas LV dyssynchrony in the lateral wall resulted in late response to CRT. [less ▲]

Detailed reference viewed: 47 (5 ULiège)
Full Text
Peer Reviewed
See detailSurgical correction of ischaemic mitral regurgitation - still a long way to go
Kolh, Philippe ULiege

in European Heart Journal (2008), 29

Detailed reference viewed: 49 (26 ULiège)
Full Text
Peer Reviewed
See detailLong-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal, Luc F; Scheen, André ULiege; Rissanen, Aila M et al

in European Heart Journal (2008), 29(14), 1761-71

AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year ... [more ▼]

AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year efficacy and tolerability data of rimonabant. METHODS AND RESULTS: Patients with a body mass index > or =30 or >27 kg/m(2) with treated/untreated hypertension, dyslipidaemia, or both, were randomized to double-blind treatment with placebo, rimonabant 5 or 20 mg once daily plus a calorie-restricted diet for 2 years. Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 20 mg produced clinically meaningful improvements in all Impact of Weight on Quality of Life-Lite questionnaire domain scores at 2 years. Rimonabant was generally well tolerated and rates of adverse events, including depressed mood disorders and disturbances were similar to placebo during year 2. Proportions of patients with clinically significant depression (Hospital Anxiety and Depression Scale score >11) were similar in all treatment groups. CONCLUSION: Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors. [less ▲]

Detailed reference viewed: 493 (1 ULiège)
Full Text
Peer Reviewed
See detailTranscatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Vahanian, Alec; Alfieri, Ottavio; Al-Attar, Nawwar et al

in European Heart Journal (2008), 29(11), 1463-70

AIMS: To critically review the available transcatheter aortic valve implantation techniques and their results, as well as propose recommendations for their use and development. METHODS AND RESULTS: A ... [more ▼]

AIMS: To critically review the available transcatheter aortic valve implantation techniques and their results, as well as propose recommendations for their use and development. METHODS AND RESULTS: A committee of experts including European Association of Cardio-Thoracic Surgery and European Society of Cardiology representatives met to reach a consensus based on the analysis of the available data obtained with transcatheter aortic valve implantation and their own experience. The evidence suggests that this technique is feasible and provides haemodynamic and clinical improvement for up to 2 years in patients with severe symptomatic aortic stenosis at high risk or with contraindications for surgery. Questions remain mainly concerning safety and long-term durability, which have to be assessed. Surgeons and cardiologists working as a team should select candidates, perform the procedure, and assess the results. Today, the use of this technique should be restricted to high-risk patients or those with contraindications for surgery. However, this may be extended to lower risk patients if the initial promise holds to be true after careful evaluation. CONCLUSION: Transcatheter aortic valve implantation is a promising technique, which may offer an alternative to conventional surgery for high-risk patients with aortic stenosis. Today, careful evaluation is needed to avoid the risk of uncontrolled diffusion. [less ▲]

Detailed reference viewed: 64 (0 ULiège)
Full Text
Peer Reviewed
See detailWhen and how does cardiac resynchronization therapy reduce dynamic mitral regurgitation?
Pierard, Luc ULiege; Lancellotti, Patrizio ULiege

in European Heart Journal (2007), 28(17), 2055-2056

Detailed reference viewed: 14 (2 ULiège)
Full Text
Peer Reviewed
See detailCystatin C blood level as a risk factor for death after heart surgery
Ledoux, Didier ULiege; Monchi, M.; Chapelle, Jean-Paul ULiege et al

in European Heart Journal (2007), 28(15), 1848-53

Detailed reference viewed: 35 (7 ULiège)
Full Text
Peer Reviewed
See detailExercise ventilation inefficiency in heart failure: pathophysiological and clinical significance
Tumminello, G.; Guazzi, M.; LANCELLOTTI, Patrizio ULiege et al

in European Heart Journal (2007), 28(6), 673-678

Heart failure (HF) is a complex syndrome characterized by myocardial dysfunction and a poor prognosis. Among multiple markers of severity, an exercise ventilation inefficiency has important clinical and ... [more ▼]

Heart failure (HF) is a complex syndrome characterized by myocardial dysfunction and a poor prognosis. Among multiple markers of severity, an exercise ventilation inefficiency has important clinical and prognostic value. The pathophysiology determining exercise ventilatory inefficiency is complex and not definitively clarified. Three different mechanisms have been identified: (i) increased dead space, (ii) early occurrence of lactic acidosis, and (iii) abnormal chemoreflex and/or metaboreflex activity. Besides its prognostic value, abnormal ventilation can be influenced by pharmacological and non-pharmacological therapies such as beta-blockers, selective cyclic 3'-5' guanosine monosphosphate phosphodiesterase inhibitors, physical training, and nocturnal continuous positive airway pressure. There is an increasing interest for the exercise periodic breathing, which is frequently associated with HF syndrome and has prognostic importance. The precise mechanisms sustaining exercise periodic breathing are not fully defined but ventilatory and metabo-haemodynamic hypotheses have been proposed. [less ▲]

Detailed reference viewed: 13 (2 ULiège)
Full Text
Peer Reviewed
See detailDeterminants of pulmonary artery hypertension at rest and during exercise in patients with heart failure
Tumminello, G.; LANCELLOTTI, Patrizio ULiege; Lempereur, Mathieu ULiege et al

in European Heart Journal (2007), 28(5), 569-574

Aims Pulmonary hypertension, a marker of poor prognosis in heart failure, may develop or increase during exercise. We sought to examine the determinants of pulmonary hypertension at rest and during ... [more ▼]

Aims Pulmonary hypertension, a marker of poor prognosis in heart failure, may develop or increase during exercise. We sought to examine the determinants of pulmonary hypertension at rest and during exercise in heart failure patients. Methods and results Forty-six patients with left ventricular (W) dysfunction (ejection fraction: 30 +/- 6%) underwent a semi-recumbent, incremental bicycle exercise Doppler echocardiography. LV systolic and diastolic function, pulmonary artery systolic pressure (PASP), functional mitral regurgitation (MR), and left atrial volume were quantified at rest and during exercise. Wide changes in PASP at exercise were unrelated to PASP at rest (r = 0.12). Independent predictors of PASP at rest were left atrial. volume (P = 0.006), E-wave velocity (P = 0.02), mitral tenting area (P = 0.005), and mitral effective regurgitant orifice (ERO) (P=0.02). The incidence of dyspnoea was similar in patients with and without moderately severe pulmonary hypertension at baseline. At peak exercise, LV ejection fraction (P = 0.03) and mitral ERO (P = 0.008) were independently associated with PASR Patients with a larger exercise increase in PASP (> 60 mmHg) interrupted frequently exercise for dyspnoea (70 vs. 27%; P = 0.04). A larger rise in mitral regurgitant volume during exercise emerged as the single determinant of exercise-induced increases in PASP. Conclusion In patients with HF, left atrial. volume, mitral deformation, and mitral regurgitant orifice correlated with pulmonary pressure at rest, whereas dynamic MR and limited contractile reserve correlated with pulmonary pressure at exercise. The magnitude of pulmonary pressure during exercise in these patients mainly depends on dynamic MR. [less ▲]

Detailed reference viewed: 67 (8 ULiège)
Full Text
Peer Reviewed
See detailA left atrial thrombus too big to embolize.
Lancellotti, Patrizio ULiege; Radermecker, Marc ULiege; Pierard, Luc ULiege

in European Heart Journal (2007), 28(13), 1660

Detailed reference viewed: 33 (5 ULiège)
Full Text
Peer Reviewed
See detailRimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Scheen, André ULiege; Van Gaal, Luc F

in European Heart Journal (2007), 28(11), 1401-21402

Detailed reference viewed: 21 (1 ULiège)
Full Text
See detailDoes treatment with erythropoietin improve left ventricular systolic performance and mitral regurgitation in patients with heart failure and chronic kidney disease?
Cosyns, B.; Lancellotti, Patrizio ULiege; Velez-Roa, S. et al

in European Heart Journal (2006, August), 27(Suppl. 1), 339

Detailed reference viewed: 14 (2 ULiège)
Peer Reviewed
See detailDeterminants of exercise-induced changes in e/ea in patients with chronic systolic left ventricular dysfunction
Lancellotti, Patrizio ULiege; Cosyns, B.; Van Camp, G. et al

in European Heart Journal (2006, August), 27(Suppl. 1), 711

Detailed reference viewed: 25 (0 ULiège)
Full Text
See detailCardiac resynchronisation therapy reduces the incidence of permanent atrial fibrillation in heart failure patients
Cosyns, B.; Lancellotti, Patrizio ULiege; Hoffer, E. et al

in European Heart Journal (2006, August), 27(Suppl. 1), 332

Detailed reference viewed: 28 (2 ULiège)
Full Text
Peer Reviewed
See detailRimonabant improves multiple cardiometabolic risk factors in diabetic and non-diabetic overweight/obese patients: data from RIO-diabetes, RIO-Europe, RIO-North America and RIO-Lipids
Scheen, André ULiege; Despres, J. P.; Pi-Sunyer, F. X. et al

in European Heart Journal (2006, August), 27(Suppl. 1), 441

Detailed reference viewed: 21 (0 ULiège)